Gain Therapeutics (NASDAQ:GANX) Stock Rating Reaffirmed by HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 304.04% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on GANX. Chardan Capital restated a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th. Oppenheimer restated an “outperform” rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Wednesday, August 14th.

Gain Therapeutics Stock Down 7.3 %

GANX opened at $1.98 on Wednesday. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $5.33. The company’s 50-day moving average price is $1.35 and its two-hundred day moving average price is $1.97. The stock has a market cap of $35.74 million, a price-to-earnings ratio of -1.32 and a beta of 0.42. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.03.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.11). As a group, equities analysts expect that Gain Therapeutics will post -1.05 earnings per share for the current year.

Insider Activity at Gain Therapeutics

In related news, Chairman Khalid Islam bought 50,000 shares of the business’s stock in a transaction on Friday, August 9th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $50,000.00. Following the purchase, the chairman now directly owns 50,000 shares in the company, valued at $50,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Gain Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of GANX. Hohimer Wealth Management LLC bought a new position in shares of Gain Therapeutics in the second quarter worth $422,000. Renaissance Technologies LLC grew its position in Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares in the last quarter. Finally, Warberg Asset Management LLC bought a new position in Gain Therapeutics in the 2nd quarter worth about $66,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.